These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36872068)

  • 1. Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.
    Stougaard EB; Rossing P; Vistisen D; Banks P; Girard M; Davies MJ; Persson F
    Diabetes Obes Metab; 2023 Jul; 25(7):1874-1882. PubMed ID: 36872068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines.
    Stougaard EB; Rossing P; Cherney D; Vistisen D; Persson F
    J Diabetes Complications; 2022 Aug; 36(8):108257. PubMed ID: 35840519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
    van Raalte DH; Bjornstad P; Persson F; Powell DR; de Cassia Castro R; Wang PS; Liu M; Heerspink HJL; Cherney D
    Diabetes Care; 2019 Oct; 42(10):1921-1929. PubMed ID: 31371432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
    Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
    Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sotagliflozin: A Review in Type 1 Diabetes.
    Deeks ED
    Drugs; 2019 Dec; 79(18):1977-1987. PubMed ID: 31761990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Bantounou MA; Sardellis P; Thuemmler R; Black Boada D; Kaczmarek J; Mahmood R; Plascevic J; Philip S
    Diabetes Obes Metab; 2024 Feb; 26(2):710-720. PubMed ID: 38031239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
    Boeder S; Edelman SV
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
    Kim YJ; Hwang SD; Lim S
    Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
    Cefalo CMA; Cinti F; Moffa S; Impronta F; Sorice GP; Mezza T; Pontecorvi A; Giaccari A
    Cardiovasc Diabetol; 2019 Feb; 18(1):20. PubMed ID: 30819210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
    Musso G; Gambino R; Cassader M; Paschetta E
    BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
    Danne T; Pettus J; Giaccari A; Cariou B; Rodbard H; Weinzimer SA; Bonnemaire M; Sawhney S; Stewart J; Wang S; Castro RC; Garg SK
    Diabetes Technol Ther; 2019 Sep; 21(9):471-477. PubMed ID: 31335194
    [No Abstract]   [Full Text] [Related]  

  • 12. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
    Sims H; Smith KH; Bramlage P; Minguet J
    Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
    Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
    Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin.
    Boeder S; Davies MJ; McGill JB; Pratley R; Girard M; Banks P; Pettus J; Garg S
    Diabetes Technol Ther; 2024 Sep; 26(9):618-625. PubMed ID: 38441906
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
    Rodbard HW; Giaccari A; Cariou B; Garg S; Davies MJ; Seth K; Sawhney S
    Diab Vasc Dis Res; 2021; 18(1):1479164121995928. PubMed ID: 33611925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
    Patel K; Carbone A
    Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis.
    Chen MB; Xu RJ; Zheng QH; Zheng XW; Wang H
    Medicine (Baltimore); 2020 Aug; 99(33):e20875. PubMed ID: 32871972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus.
    Vitale RJ; Laffel LM
    Adv Chronic Kidney Dis; 2021 Jul; 28(4):309-317. PubMed ID: 34922687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.
    Hinton W; Ansari AS; Whyte MB; McGovern AP; Feher MD; Munro N; de Lusignan S
    Diabetes Obes Metab; 2023 Feb; 25(2):501-515. PubMed ID: 36239122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.